Dr. Salerno Discusses Hypofractionation for Early Breast Cancer

Kilian Salerno, MD
Published: Friday, Apr 01, 2016



Kilian Salerno, MD, director of Breast Radiation and Soft Tissue/Melanoma Radiation, Roswell Park Cancer Institute, discusses hypofractionated radiotherapy for the treatment of patients with early-stage breast cancer. Salerno addressed the topic of NCCN guideline updates in breast cancer at the 2016 NCCN Annual Conference.

There is compelling evidence that hypofractionation to the whole breast elicits equivalent, if not better, outcomes for women compared with the conventional regimen. Data from two large studies showed that in addition to outcomes, cosmetic outcomes were also the same, if not better, and toxicity was more tolerable for patients.

Salerno says the tweaking of the guidelines to state that hypofractionation is “preferred” is an important change. She says she hopes that it will lead to greater adoption throughout the United States.

<<< View more from the 2016 NCCN Annual Conference



Kilian Salerno, MD, director of Breast Radiation and Soft Tissue/Melanoma Radiation, Roswell Park Cancer Institute, discusses hypofractionated radiotherapy for the treatment of patients with early-stage breast cancer. Salerno addressed the topic of NCCN guideline updates in breast cancer at the 2016 NCCN Annual Conference.

There is compelling evidence that hypofractionation to the whole breast elicits equivalent, if not better, outcomes for women compared with the conventional regimen. Data from two large studies showed that in addition to outcomes, cosmetic outcomes were also the same, if not better, and toxicity was more tolerable for patients.

Salerno says the tweaking of the guidelines to state that hypofractionation is “preferred” is an important change. She says she hopes that it will lead to greater adoption throughout the United States.

<<< View more from the 2016 NCCN Annual Conference




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x